-
Lifespan Portfolio Company Rejuvenate Bio Closes $6 Million Financing and R&D Collaboration with Merck Animal Health
Milestone financing and R&D collaboration advances gene therapy programs targeting chronic and age-related diseases in companion animals. NORWALK, Conn., June 11, 2026 /PRNewswire/ — Lifespan Vision Ventures (LVV), an investment firm focused on therapeutics that improve human healthspan, congratulates its portfolio company Rejuvenate Bio on the successful close of a $6 million financing round and…
-
Zealand Pharma – Transactions related to share buy-back program (week 22, 2026)
Company announcement No. 20 / 2026 Zealand Pharma – Transactions related to share buy-back program (week 22, 2026) Copenhagen, Denmark, June 1, 2026 – Zealand Pharma A/S (“the Company” or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today reports transactions related to its share buy-back program (the…
Latest News
About the Author
We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.